**Proteins** 

# **Product** Data Sheet

## **ZED-1227**

Cat. No.: HY-19359 CAS No.: 1542132-88-6 Molecular Formula:  $C_{26}H_{36}N_6O_6$ Molecular Weight: 528.6

Target: Glutaminase

Pathway: Metabolic Enzyme/Protease -20°C Storage: Powder 3 years

> 2 years -80°C In solvent 6 months

> > -20°C 1 month

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 125 mg/mL (236.47 mM; Need ultrasonic)

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.8918 mL	9.4589 mL	18.9179 mL
	5 mM	0.3784 mL	1.8918 mL	3.7836 mL
	10 mM	0.1892 mL	0.9459 mL	1.8918 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.08 mg/mL (3.93 mM); Suspended solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (3.93 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.93 mM); Clear solution

### **BIOLOGICAL ACTIVITY**

Description ZED-1227 is a specific and orally active transglutaminase 2 (TG2) inhibitor, with an IC<sub>50</sub> of 45 nM. ZED-1227 can block inflammation-induced TG2 expression and activity. ZED-1227 can be used for the research of celiac disease (CeD)<sup>[1][2]</sup>.

IC50: 45 nM (TG2)[2] IC<sub>50</sub> & Target

In Vitro  $ZED-1227~(0.1~\mu\text{M}-1~\mu\text{M}; 24~hours)~has~no~effect~on~metabolic~activity~and~proliferation~in~Huh7~cells~and~CaCo2~cells,?~that~cells~and~caCo2~cells~and~$ suggests ZED-1227 has no cytotoxic activity<sup>[2]</sup>.

		?ZED-1227 (0.002-0.2 mg/mL; 30 minutes) inhibits TG2 in the small intestinal mucosa in vitro <sup>[2]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	levels and subdues inte ?ZED-1227 (5 mg/kg; i.g	ZED-1227 reduces the activity of intestinal TG2 induced by Polyinosinic:Polycytidylic acid (40 mg/kg) to normal control levels and subdues intestinal inflammation in mice <sup>[1]</sup> .  ?ZED-1227 (5 mg/kg; i.g.) is able to inhibit TG2 in the small intestinal mucosa <sup>[2]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	BALB/c mice <sup>[2]</sup>		
	Dosage: Administration:	5 mg/kg Oral gavage		
	Result:	Inhibited TG2 in vivo in the small intestinal mucosa.		

#### **REFERENCES**

[1]. Manu Encalada, et al. The Oral Transglutaminase 2 (TG2) Inhibitor Zed1227 Blocks TG2 Activity in a Mouse Model of Intestinal Inflammation. Gastroenterology. 154(6):S-490.

[2]. Christian Büchold, et al. Pyridinone derivatives as tissue transglutaminase inhibitors. WO2014012858A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech @ Med Chem Express.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA